Stoke Therapeutics Q3 EPS $(0.55) Beats $(0.63) Estimate, Sales $3.31M Beat $3.19M Estimate
Portfolio Pulse from Benzinga Newsdesk
Stoke Therapeutics reported Q3 losses of $(0.55) per share, beating the analyst consensus estimate of $(0.63) by 12.7%. This is a 16.67% increase over losses from the same period last year. The company also reported quarterly sales of $3.31 million, beating the analyst consensus estimate of $3.19 million by 3.70%. This is a 13.87% increase over sales from the same period last year.
November 07, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stoke Therapeutics reported better than expected Q3 results, with losses and sales beating analyst estimates.
Stoke Therapeutics reported Q3 losses of $(0.55) per share, beating the analyst consensus estimate of $(0.63) by 12.7%. This is a 16.67% increase over losses from the same period last year. The company also reported quarterly sales of $3.31 million, beating the analyst consensus estimate of $3.19 million by 3.70%. This is a 13.87% increase over sales from the same period last year. These better than expected results could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100